reason report
robot readthrough follow acquisit auri
bottom line morn op announc agreement
acquir privately-held auri health cash addit
conting milestone-bas payment auri health
develop robot technolog alreadi fda-approv
platform initi focus lung cancer expect eventu
expand area background deal rumor
recent week ago given invest
auri develop corpor arm isnt terribl
surpris us view deal posit
margin given reinforc compani commit
robot give earlier entri robot market
already-approv platform addit note follow-
convers eventu compani look leverag auri
plu recently-acquir neuwav microwav ablat therapi
develop combin diagnostic/therapeut robot ecosystema
combin diagnostic/therapeut applic singl flex cathet
robot platform someth medacorp physician check
suggest could killer app eventu work
similar capabl howev type advanc system still
like year either compani view
manag competit headlin risk broadli dont
think deal chang much within robot competit
landscap least near-to-intermedi term given
auri alreadi approv hand larger
scaleabl player confirm chang
timelin robot platform verb gener surgeri
soft launch still expect geographi like ex-u
end
implic jnj robot initi chang verb/
orthotaxi timelin step right direct becom
robot player confirm acquisit auri doesnt
chang timelin verb compani last commun
would undergo soft launch geographi indic
end auri bring alreadi approv robot
platform relev product develop capabl
know-how compani believ leverag across
robot initi given like dr freder moll founder
ceo auri join auri monarch system specif compet
isrg op ion launch expect ion smaller
cathet vs monarch believ surgic field
monarch competit advantag enabl visual
throughout procedur also lead larger diamet cathet
pleas refer page import disclosur price chart analyst certif
due camera intern posit wed note management
highlight differ cathet size sens capabl -- -ion
endpoint sens capabl shape-sens technolog acquir
luna technolog -- believ could offer safeti efficaci
advantag favor ion right monarch ion system
target lung biopsy/diagnost ultim long-term goal
develop combin diagnostic/therapeut deliveri capabl initi
lung cancer eventu expand indic toward
end look combin monarch recently-acquir
neuwav microwav ablat technolog develop combin
diagnostic/abl tool initi lung cancer eventu expand
indic one-shot system like year
note iter combin system could enter market
think like still activ medic devic base
math capac lever
done us largest white space
lack scale devic remain cardiolog innov
continu matter much scale cardiolog -- evidenc
continu strong double-digit growth within biosens webster
busi -- believ scale multi-lin product offer could
eventu necessari compet effect sometim
futur recent earn call ww chairman
medic devic ashley mcevoy note ask analyst
compani alway look transform relat
potenti target continu believ op make
sens given breadth depth product offer vs
concentr vertic would get acquisit ew
implic perhap add headlin risk noth
major alreadi expect view robot contend
new news competit threat least headlin perspect
manageable/limit near-to-intermedi term
gen surgeri robot categori view respect
lung cancer diagnostic/therapeut procedur acquir auri
known technolog investor actual
see potenti posit readthrough take bit
x-factor tabl whether jnj/mdt mp go leapfrog
innov front someth unknown auri
suggest might necessarili case given go
flex cathet robot arena known entiti flip
side increment neg implic perhap potenti
make auri surgic tougher competitor hand front
isrg about-to-launch ion system intend
applic lung biopsi diagnost anticip mid-year launch
howev view complementari solut round
jnj digit surgeri ecosystem littl suggest acceler
and/or innov capabl on-going verb platform view
believ verb robot earliest track soft launch
gen surgeri within one global region necessarili us
procedur indic unclear suspect well get
detail around jnj mdt robot strategies/ timelin
upcom societi american gastrointestin endoscop surgeon
sage confer april baltimor md
upcom industri confer like forum learn
competitor robot initi gener surgeri
robot platform jnj/mdt look upcom sage
confer baltimor md next event/plac
suspect could get updat mdt robot
initi possibl even includ auris-jnj combin
jnj orthoped robot initi suspect well get updat
upcom american academi orthopaed surgeon aao
confer la vega management host
investor event large-cap ortho player host investor event
believ jnj orthoped robot initi involv
approach two system earlier-to-market system leverag
brainlab cirq robot arm exclus prefer agreement
last check-in nass north american spine societi
fall cirq pend clearanc statu unclear
understand nexgen version could avail sometim
long-term robot initi involv jnj purchas
believ system first commerci avail total knee like
time-frame management goal ubiquit system
broad reach across spine hip knee orthotaxi spine
like come sometim total knee estim like
daniel antalffi certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
richard newitt certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori boston scientif corpor
leerink place outperform rate januari
creat bluematrix
next month believ share trade deriv appli price-to-earnings multipl
cash ep estim assum stabl multipl current price-to-earnings multipl ep
slightli price-to-earnings large-cap med-tech group broadli
top-tier sale growth profil mid-to-high singl digit rang healthier balanc sheet head
think premium multipl justifi compani continu deliv solid execut consist meet-or-
beat quarter also ramp key new product move past litig issu see opportun
multipl expans ahead
risk valuat
risk includ lack meaning recoveri med-tech market broadli major market
drug-elut stent de cardio rhythm monitor specif failur success execut
key new product launch major litig loss potenti product recal particularli within
inabl suffici reduc cost drive oper margin expans
rate price target histori edward lifesci corpor ew
leerink initi coverag ew outperform rate januari
creat bluematrix
price target previous appli price-to-earnings multipl ep
estim pt assum multipl contract current ep still
large-cap group averag also think ew market-lead posit highli under-penetrated
total address market justifi compani premium valuat rel rest large-cap med-tech
risk valuat
risk includ inflect point intermedi risk adopt ramp neg competit clinic data and/or
competit launch delay faster-than-expect low risk asymptomat trial ramp earlier-than-
rate price target histori intuit surgic inc
leerink place outperform rate octob
creat bluematrix
valuat base dcf analysi yield pt discount rate calcul use
capm model current trade price-to-earnings ex-cash basi incl cash
ex-cash incl cash vs broader market cap med-tech average incl ew
pt impli appli adj ep less int incom
cash believ isrg premium group sustain given above-averag top- bottom-lin growth
potenti vs peer amid multipl new product cycl help drive increas penetr still-larg
risk valuat
risk valuat includ high volatil wide-trad rang stock compani relianc singl
product robot potenti chang wors hospit capit spend environ continu
debat around cost/benefit come adopt robot procedur current project valuat
could risk gyn/uro trend slow greater degre model newer gener surgeri robot
procedur slower expect adopt forecast anticipated-to-launch nexgen sp platform
delay fail gain traction launch compani cant achiev revenu contribut
model flexibl cathet robot program key risk includ ou growth slower
anticip -- -either due delay develop new japan procedur opportun and/or new china system tender/
quota newer robot entrant mdt/jnj beyond come onto scene result
competit trial potenti caus hospit purchas cycl elong given robot solut
evalu sg invest combat competit develop new market lead greater opex
spend -- -potenti limit near-term earn power -- -v weve model
rate price target histori johnson johnson
leerink place outperform rate januari
creat bluematrix
next month believ share trade price target price target appli price-to-earnings
multipl ep estim share current trade ep estim
large-cap med-tech group rang price target assum
see multipl expans line broader comp group compani manag
top-lin headwind continu manag cost benefit actelion -- posit
sustain ep out-performance view total return capabl attract increasingli volatil
stock market environ like attract fund riskier area
risk valuat
risk includ failur success integr actelion amo synth potenti futur acquisit
failur resolv outstand consum consent decre success re-launch product product
recal failur advanc late-stag pipelin success launch new product protract recoveri
procedur volum trend lack real macroeconom recoveri
rate price target histori medtron plc
leerink place market perform rate jan
creat bluematrix
share current trade ep assum stabl multipl current
multipl ep estim moder area broader large-cap
med-tech univers though believ could eventu return path consist mid-
single-digit top-lin growth time less certain see limit multipl expans
mid-single-digit growth trajectori larg predic recent upcom new product launch sustain
trend without risk price target appli basic stabl multipl
ep estim
risk valuat
risk valuat includ continu signific spine market spine sale declin market fail regain
deliv product pipelin failur success execut cost save initi
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
